Press Release   -

Digital PCR (dPCR) And qPCR Market to Reach USD 1.60 Billion by 2028

According to a new report by Vantage Market Research, the digital PCR (dPCR) and qPCR market is expected to reach USD 1.60 Billion by 2028, growing at a CAGR of 7% from 2021 to 2028. Rising prevalence of genetic disorders and infectious diseases and increase in number of hospitals and diagnostic centers are the major determinants anticipated to drive the market globally. 

Key Findings:    

• Under the Product segment, instruments sub-segment is projected to grow at a CAGR of over 11.3% over the forecast period owing to the increasing adoption in the manufacturing industry.
• The industry segment held a market share of around 31.25% in 2020. This share is due to the increasing utilization in processing industry among countries such as China, India, and U.S, and Germany.
• North America is expected to expand at a CAGR over 12.2% from 2021 to 2028. This surge is attributed to the rising demand for upcoming industries and rapid development in this sector in countries in U.S. and Canada.

Some of key players in digital PCR (dPCR) and qPCR market include Techne, TaKaRa, Hongshi Medical Technology, Quanta, Eppendorf, Biometra, Hema Medical Instrument, Thermo Fisher Scientific, Agilent, Cepheid, Peqlab, Bio-rad, Bioer., and among others.

The most important application of PCR is either to amplify DNA, quantify it, or do both in the same reaction. In conventional PCR, the DNA of interest is amplified to take more than one copy because single or double DNA molecules are not sufficient for downstream analyses. However, gene measurement using conventional PCR is not possible, so gene expression and nucleic acid measurement cannot be done with conventional PCR. Developing business sectors are relied upon to offer huge development openings because of the rising frequency of irresistible and persistent sicknesses just as expanding R&D drives to create imaginative genomic methods like qPCR and dPCR. The development in these business sectors is upheld by the extension of medical services foundation, expansion in medical care consumption, and decreasing procedural expenses for qPCR and dPCR-based sickness analysis. Arising nations are seeing quick modernization in medical services offices and the development of medical services framework. This factor is adding to the developing interest for clinical demonstrative systems among symptomatic labs, which is bringing about the expanded deals of clinical qPCR and dPCR items.

North America is relied upon to rule the qPCR and dPCR market, trailed by Europe. Development in the North American qPCR and dPCR market will be pushed by expanded reception of inventive and novel investigation items (counting progressed qPCR and dPCR items), accessibility of R&D financing for genomic research (combined with the strong examination foundation in the district), growing utilization of PCR procedures in clinical diagnostics and legal sciences, and early commercialization of qPCR/dPCR items contrasted with different areas.